• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环丙沙星与磷霉素对革兰氏阴性菌的体外协同作用。

Synergism between ciprofloxacin and fosfomycin against gram-negative bacteria in vitro.

作者信息

Vogt K, Hahn H

机构信息

Institut für Medizinische Mikrobiologie der Freien Universität, Berlin.

出版信息

Zentralbl Bakteriol. 1989 Dec;272(2):225-30. doi: 10.1016/s0934-8840(89)80011-8.

DOI:10.1016/s0934-8840(89)80011-8
PMID:2631736
Abstract

A combination of ciprofloxacin and fosfomycin was evaluated for synergism employing time-kill experiments. A total of 59 clinical isolates of gram-negative bacteria was examined. All organisms were moderately sensitive or resistant to ciprofloxacin; 72.9% also showed moderate sensitivity or resistance to fosfomycin. After 24 h, synergism was seen in 22% of the strains, i.e. less than reported by other authors. There was no correlation between synergistic action and sensitivity to ciprofloxacin and fosfomycin, respectively.

摘要

采用时间杀菌实验评估环丙沙星和磷霉素联合使用的协同作用。共检测了59株革兰氏阴性菌临床分离株。所有菌株对环丙沙星均为中度敏感或耐药;72.9%的菌株对磷霉素也表现出中度敏感或耐药。24小时后,22%的菌株出现协同作用,即低于其他作者报道的比例。协同作用与对环丙沙星和磷霉素的敏感性之间分别无相关性。

相似文献

1
Synergism between ciprofloxacin and fosfomycin against gram-negative bacteria in vitro.环丙沙星与磷霉素对革兰氏阴性菌的体外协同作用。
Zentralbl Bakteriol. 1989 Dec;272(2):225-30. doi: 10.1016/s0934-8840(89)80011-8.
2
In vitro activity of fosfomycin against 'problem' gram-positive cocci.磷霉素对“棘手”革兰氏阳性球菌的体外活性
Microbios. 1992;71(287):95-103.
3
Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.环丙沙星与磷霉素对囊性纤维化患者分离出的铜绿假单胞菌的体外协同作用。
J Antimicrob Chemother. 1988 Jul;22(1):41-50. doi: 10.1093/jac/22.1.41.
4
[In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa].磷霉素单独或联合使用对耐碳青霉烯类铜绿假单胞菌临床分离株的体外活性
Enferm Infecc Microbiol Clin. 2016 Apr;34(4):228-31. doi: 10.1016/j.eimc.2015.06.016. Epub 2015 Aug 12.
5
Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.评价三甲氧氨磷霉素在土耳其社区获得性和医院获得性尿路感染分离的革兰阴性菌中的体外活性。
Int J Infect Dis. 2013 Nov;17(11):e966-70. doi: 10.1016/j.ijid.2013.04.005. Epub 2013 Jun 3.
6
Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.甲氧苄啶与环丙沙星对临床分离细菌的体外协同作用。
Eur J Clin Microbiol Infect Dis. 1992 Mar;11(3):255-7. doi: 10.1007/BF02098092.
7
In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.磷霉素与头孢他啶、亚胺培南、阿米卡星及环丙沙星联合对铜绿假单胞菌的体外活性
Eur J Clin Microbiol Infect Dis. 1997 Feb;16(2):159-62. doi: 10.1007/BF01709477.
8
The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.捷克共和国尿路感染分离出的革兰氏阴性菌对磷霉素的敏感性:一项单中心研究的数据
BMC Urol. 2017 Apr 26;17(1):33. doi: 10.1186/s12894-017-0222-6.
9
Fosfomycin.磷霉素
Clin Microbiol Rev. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15.
10
Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.磷霉素与多黏菌素B、妥布霉素或环丙沙星联用的临床相关浓度可增强对铜绿假单胞菌的杀菌作用,但不能抑制磷霉素耐药性的产生。
J Antimicrob Chemother. 2016 Aug;71(8):2218-29. doi: 10.1093/jac/dkw115. Epub 2016 Apr 26.

引用本文的文献

1
Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.磷霉素作为全身感染管理的联合用药。对其体外和体内研究协同特性的系统评价。
Antibiotics (Basel). 2020 Aug 10;9(8):500. doi: 10.3390/antibiotics9080500.